{'fraction_non_alphanumeric': 0.0196078431372549, 'fraction_numerical': 0.032679738562091505, 'mean_word_length': 5.160919540229885, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The clinical value of tissue polypeptide antigen in ovarian carcinoma].

OBJECTIVE
To evaluate the clinical usefulness of tissue polypeptide antigen (TPA) in diagnosis and monitoring the course of patients with ovarian carcinoma.


METHODS
Serum levels of TPA and cancer antigen 125 (CA125)were measured by radioimmunoassay in 60 patients with advanced ovarian carcinoma (41 with active disease and 16 with nonactive, 3 with metastatic tumor from gastrointestinal carcinoma), 24 healthy women and 27 benign gynecologic tumors.


RESULTS
The serum TPA and CA125 levels were elevated in 82% and 70% of patients with ovarian carcinoma respectively, the total positive rate of the two markers was 92%. TPA and CA125 levels were within normal range among most of healthy women and patients with benign tumors. TPA and CA125 levels were also correlated with the regression or progression of the disease.


CONCLUSION
Combined measurement of TPA with CA125 was useful for the differential diagnosis and achieving higher positivity in patients with epithelial ovarian carcinoma.